News
Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...
Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.
For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...
Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.
Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.
Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...
Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.
USA: Atopic eczema (AE), including AE severity, is linked with a decreasing lymphocyte count, regardless of the use of the ...
Get insights on Corvus Pharmaceuticals' Q2 2025 earnings call. Learn about soquelitinib's clinical progress, Phase II trial plans, and financial strategies.
18h
HealthDay on MSNLebrikizumab Efficacious, Safe for Patients With Skin of Color, Eczema
For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the American Journal of Clinical Dermatology. Andrew ...
Eli Lilly (LLY) recently introduced EBGLYSS through Senderra Specialty Pharmacy, targeting patients with atopic dermatitis, ...
Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results